A technology company that searches and analyzes natural immune systems to find antibodies.
3 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about AbCellera Biologics Inc..
The 2 sources with the most insights about AbCellera Biologics Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Has a market cap of $3.68B and 18.83% short interest as a percentage of float.
Stock jumped over 30% to 37% following positive Phase 2 clinical trial results, providing a new valuation floor.
Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.
Has a market cap of $3.68B and 18.83% short interest as a percentage of float.
Stock jumped over 30% to 37% following positive Phase 2 clinical trial results, providing a new valuation floor.
Mentioned as one of the heavily shorted, smaller-cap stocks that saw significant gains due to a 'risk-on' appetite and speculative fervor in the market.
Other assets that creators frequently mention in the same content as AbCellera Biologics Inc..
The most active sources covering AbCellera Biologics Inc. (ABCL) on Kazuha are @amitinvesting, SgtWingflapper. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about AbCellera Biologics Inc. (ABCL) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering AbCellera Biologics Inc. (ABCL) most frequently also discuss GOOGL, COIN, WYFI, MSTR, INTC. See the "Discussed alongside" section above for full asset pages.